Cite
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design.
MLA
Broglio, Kristine, et al. “PET-CR as a Potential Surrogate Endpoint in Untreated DLBCL: Meta-Analysis and Implications for Clinical Trial Design.” Leukemia & Lymphoma, vol. 63, no. 12, Dec. 2022, pp. 2816–31. EBSCOhost, https://doi.org/10.1080/10428194.2022.2095624.
APA
Broglio, K., Kostakoglu, L., Ward, C., Mattiello, F., Sahin, D., Nielsen, T., McGlothlin, A., Elliott, C. F., Witzig, T., Sehn, L. H., Trnĕný, M., Vitolo, U., Martelli, M., Foster, M., Wendelberger, B., Nowakowski, G., & Berry, D. A. (2022). PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. Leukemia & Lymphoma, 63(12), 2816–2831. https://doi.org/10.1080/10428194.2022.2095624
Chicago
Broglio, Kristine, Lale Kostakoglu, Carol Ward, Federico Mattiello, Denis Sahin, Tina Nielsen, Anna McGlothlin, et al. 2022. “PET-CR as a Potential Surrogate Endpoint in Untreated DLBCL: Meta-Analysis and Implications for Clinical Trial Design.” Leukemia & Lymphoma 63 (12): 2816–31. doi:10.1080/10428194.2022.2095624.